Mayo Foundation for Medical Education and Research

Celyad S.a.

Cardio3 Biosciences S.a.

Atta Behfar

Andre Terzic

Ruben Jose Crespo-Diaz

Christian Homsy

Roland Gordon-Beresford

Michael V Callahan

William Cook

Ruben Crespo

Soulmaz Boroumand

Vinciane Gaussin

This document relates to methods and materials for making and using cardiopoetic stem cells. For example, methods and materials for delivering one or more nucleic acids (e.g., one or more RNAs) encoding one or more early mesodermal transcription factors to a stem cell to generate a cardiopoetic stem cell are provided.

Making and using cardiopoietic cells

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)) are provided.

Method of using NAP-2 and TGF-α to improve cardiac function

A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA may be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.

Particle-mediated delivery of biologics

A purified exosome product includes spherical or spheroid exosomes with a diameter no greater than 250 nm. In some embodiments, the purified exosome product has a moisture content of no more than 10%. The purified exosome product can be reconstituted to prepare an artificial blood product.

Purified exosome products, method of making, and methods of using

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk for experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCT) for ST-elevation myocardial infarction (STEMI) are provided.

Using nucleic acids encoding NAP-2 polypeptides to improve cardiac function

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.

NAP-2 polypeptides and methods for modulating immune system activity in heart tissue

A method of delivering exosomes and other micro vesicles to a biological target includes the steps of 1) providing blood, (2) separating plasma from the provided blood, and (3) separating the solution with the exosomes therefrom, (4) encapsulating the exosomes, and (5) delivering the exosomes. The step of encapsulation may be accomplished by water bead process, alginate bead process, spray drying bead formation, or plating. The biological target may be a human or animal heart, bone/joint, wound or skin. A method of encapsulating an exosome, a method of using an encapsulated exosome, compositions including encapsulated exosomes, and an encapsulated exosome per se are also disclosed.

Exosome delivery technology

This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the obtained cells to heart tissue.

Compositions and methods for obtaining cells to treat heart tissue

Using nucleic acids encoding NAP-2 and TGF-alpha polypeptides to improve cardiac function

This document provides methods and materials relating to cardiac cells. For example, this document provides methods and materials that can be used to obtain cells having the ability to differentiate into cardiomyocytes. Such cells can be used to repair damaged heart tissue. For example, cells having the ability to differentiate into cardiomyocytes can be used to repair or regenerate heart tissue in patients with a cardiac condition (e.g., ischemic cardiomyopathy, myocardial infarction, or heart failure).

Methods and materials for providing cardiac cells

This document provides methods and materials for treating cardiovascular tissue. For example, stem cells, compositions containing stem cells, methods for obtaining stem cells, compositions for generating stem cells expressing particular markers, and methods for repairing cardiovascular tissue are provided.

Treating cardiovascular tissue

This document provides methods and materials for treating cardiovascular tissue. For example, stem cells, compositions containing stem cells, methods for obtaining stem cells, compositions for generating stem cells expressing particular markers (e.g., compositions comprising TGF-&#x3b2;1, BMP-2, FGF-4, and leukemia inhibitory factor), and methods for repairing cardiovascular tissue are provided.

Growing community of inventors

Rochester, MN, United States of America

Atta Behfar